Latest News of CAPL
Intra-Cellular bolsters Caplyta data with another Phase III win
By Yahoo! Finance |
1 week ago
Intra-Cellular Therapeutics reports positive results from a Phase III trial of Caplyta for preventing relapse in schizophrenia patients. The study showed a 63% reduction in relapse risk with Caplyta c...